Long-term persistence of second-line biologics in psoriatic arthritis patients with prior TNF inhibitor exposure: a nationwide cohort study from the French health insurance database (SNDS)

INTRODUCTION: Tumour necrosis factor inhibitor (TNFi) agents are most often the first-choice biological treatment for patients with psoriatic arthritis (PsA). When their discontinuation is needed, a switch to another TNFi or to another therapeutic class may be considered. However, data supporting on...

Descripción completa

Detalles Bibliográficos
Autores principales: Pina Vegas, Laura, Hoisnard, Léa, Bastard, Léa, Sbidian, Emilie, Claudepierre, Pascal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730400/
https://www.ncbi.nlm.nih.gov/pubmed/36597983
http://dx.doi.org/10.1136/rmdopen-2022-002681

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730400/
https://www.ncbi.nlm.nih.gov/pubmed/36597983
http://dx.doi.org/10.1136/rmdopen-2022-002681

Ejemplares similares